Covid: Natco Pharma seeks approval for Molnupiravir capsules phase 3 trials


 Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organization (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.

American pharma major Merck along with Ridgeback Biotherapeutics has developed Molnupiravir(MK-4482).

According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.

"Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy," it said.

NATCO is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients. Read More

Comments

Popular posts from this blog

Cafe Coffee Day names S V Ranganath as interim chairman

Kohli only Indian among Forbes highest paid athletes, Messi tops the list

Mia Khalifa engaged to beau Robert Sandberg